Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$100,000.00

The role of endothelial glutamine metabolism in control of angiogenesis

FY 2011-12

Summary
Growth of new blood vessels (angiogenesis) supplies oxygen and nutrients to normal cells and tissues as our bodies develop, grow and change throughout life. In some diseases, including cancer, angiogenesis becomes abnormal, and contributes to disease progression. In cancer, abnormal angiogenesis occurs within tumours, and allows tumours to grow and spread. Like other cells, tumour cells require a blood supply to survive. Therefore, eliminating the blood supply to tumours is one strategy for fighting cancer. There are many signals that trigger angiogenesis in tumours. Some current cancer treatments block these signals, in an effort to prevent the growth of new blood vessels and to starve the tumour. The problem with this approach is the multitude of signals: if we block one signal from the tumour, another signal may still promote blood vessel growth. The goal of this work is to target the cells that make new blood vessels (endothelial cells or ECs) directly: rather than attempt to block signals to these cells, we will stop the cellular processes that allow ECs to grow and divide. ECs undergo a significant change when they shift from a resting state to an active state. In their active state, they begin to grow, migrate, and multiply, and to form new blood vessels. In order to change from resting to active, ECs must change the way they produce energy. Evidence indicates that glutamine, an amino acid that is abundant in the blood, is required for ECs to undergo this switch. In these experiments, we will 1) study the role of glutamine in ECs, and 2) use animal models to determine how glutamine contributes to the formation of new blood vessels in normal embryonic development and in cancer. We will use mice implanted with various types of tumours to determine whether interfering with glutamine is an effective cancer therapy. Targeting EC metabolism directly is a completely new approach to cancer treatment, and may prove effective against many different types of cancer.
Program
CIHR Fellowship
Location
Belgium
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
255743
Name
Ramer Leanne
Country
Belgium
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
The role of endothelial glutamine metabolism in control of angiogenesis
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Blood Vessel Sprouting; Conditional Knock-Out; Laser-Capture Micro-Dissection; Orthotopic Tumours; Quantitative Pcr; Retinal Angiogenesis
Abstract
Growth of new blood vessels (angiogenesis) supplies oxygen and nutrients to normal cells and tissues as our bodies develop, grow and change throughout life. In some diseases, including cancer, angiogenesis becomes abnormal, and contributes to disease progression. In cancer, abnormal angiogenesis occurs within tumours, and allows tumours to grow and spread. Like other cells, tumour cells require a blood supply to survive. Therefore, eliminating the blood supply to tumours is one strategy for fighting cancer. There are many signals that trigger angiogenesis in tumours. Some current cancer treatments block these signals, in an effort to prevent the growth of new blood vessels and to starve the tumour. The problem with this approach is the multitude of signals: if we block one signal from the tumour, another signal may still promote blood vessel growth. The goal of this work is to target the cells that make new blood vessels (endothelial cells or ECs) directly: rather than attempt to block signals to these cells, we will stop the cellular processes that allow ECs to grow and divide. ECs undergo a significant change when they shift from a resting state to an active state. In their active state, they begin to grow, migrate, and multiply, and to form new blood vessels. In order to change from resting to active, ECs must change the way they produce energy. Evidence indicates that glutamine, an amino acid that is abundant in the blood, is required for ECs to undergo this switch. In these experiments, we will 1) study the role of glutamine in ECs, and 2) use animal models to determine how glutamine contributes to the formation of new blood vessels in normal embryonic development and in cancer. We will use mice implanted with various types of tumours to determine whether interfering with glutamine is an effective cancer therapy. Targeting EC metabolism directly is a completely new approach to cancer treatment, and may prove effective against many different types of cancer.
Competitiondate
201202
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Ramer, Leanne
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~
Direct Payment - $100,000 Grant (2011-12) | Canada Spends